Is matcha an appetite suppressant? One serving vs the trials
Is matcha an appetite suppressant? NIH's trial summary reports weight, not hunger. One lab-tested 2 g serving set against the trial catechin doses.
Weight-loss supplements, weighed honestly
Is matcha an appetite suppressant? NIH's trial summary reports weight, not hunger. One lab-tested 2 g serving set against the trial catechin doses.
Does Alpha Lion fat burner work? SuperHuman Burn's 500 mg MitoBurn and 40 mg CaloriBurn were trialled for 56 days: no significant fat-mass gap vs placebo.
What is a thermogenic fat burner? A supplement sold to raise heat output and calorie burn. Six NIH-listed ingredients, set against what each did to weight.
Is OxyShred a fat burner? It is sold as one. Its published trial gave one serving to 23 women for 180 minutes and reports calories burned, not fat lost.
Does a fat burner work? A 21-study meta-analysis found limited benefit. Five common ingredients checked against the NIH weight-loss supplement fact sheet.
Is caffeine an appetite suppressant? Weakly and briefly, on the trials. Three doses converted to milligrams and set against the FDA's 400 mg daily figure.
What is a good appetite suppressant? Five supplement ingredients, each with its trial's weight figure, set against the 5% prescription average.
Calocurb reviews sorted by who wrote them and who paid, from a 4.3-star brand widget to a 24-week trial, plus what a 90-capsule bottle costs per day.
How to take Calocurb: the brand's schedule, the CLINICAL label and the C4 trial protocol side by side, converted to mg of Amarasate a day.
What is Amarasate? The New Zealand bitter hop extract inside Calocurb, with each brand claim set against the four human trials we read.
Calocurb is a supplement with one 24-week, 150-person trial (4.3% vs 0.5%). Ozempic is an FDA-approved diabetes drug with a boxed warning. Side by side.
Calocurb side effects, counted: the 24-week C4 trial's withdrawals and dose cuts for diarrhea and nausea, set against the brand pages' 'rare' and 'mild'.
Yes: one 24-week placebo-controlled trial, company-funded. Calocurb lost 4.3% vs 0.5% on placebo, a 3.8-point gap, at the label's maximum dose.